Global Hunter Securities Reiterates a 'Buy' on Savient Pharmaceuticals (SVNT); Acquisition Talks Continue; No Salesforce Identified Yet
Tweet Send to a Friend
Global Hunter Securities reiterates a 'Buy' rating on Savient Pharmaceuticals (Nasdaq: SVNT), raises PT from $19 to $23.
Global analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Global analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
